Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis bacillus calmetteguerin producing a pertussis toxin- tetanus toxin hybrid protein

Infection and Immunity

Volumn 67, Issue 10, 1999, Pages 5100-5105

  Abomoelak, B ^a   Huygen, K ^b   Kremer, L ^a   Turneer, M ^b   Locht, C ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HYBRID PROTEIN; PERTUSSIS TOXIN; RECOMBINANT VACCINE; TETANUS TOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; GENE EXPRESSION SYSTEM; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROMOTER REGION; TETANUS; TUBERCULOSIS;

EID: 0344631617     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.10.5100-5105.1999     Document Type: Article

References (42)

1. Abomoelak, B., et al. Unpublished data.
2. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet i:955-960. (Erratum, Lancet i:1238).
3. Aldovini, A., and R. A. Young. 1991. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351:479-482.
4. Bange, F.-C., A. M. Brown, and W. R. Jacobs, Jr. 1996. Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages. Infect. Immun. 64:1794-1799.
5. Barry, E. M., O. Gomez-Duarte, S. Chatfield, R. Rappuoli, M. Pizza, G. Losonsky, J. Galen, and M. M. Levine. 1998. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD908. Infect. Immun. 64:4172-4181.
6. Bass, J. W., and S. R. Stephenson. 1987. The return of pertussis. Pediatr. Infect. Dis. J. 6:141-144.
7. Baulard, A., C. Jourdan, A. Mercenier, and C. Locht. 1992. Rapid mycobacterial plasmid analysis by electroduction between Mycobacterium spp. and Escherichia coli. Nucleic Acids Res. 20:4105.
8. Baulard, A., L. Kremer, P. Supply, D. Vidaud, J.-M. Bidart, D. Bellet, and C. Locht. 1996. A new series of mycobacterial expression vectors for the development of live recombinant vaccines. Gene 176:149-154.
9. Baulard, A., L. Kremer, and C. Locht. Unpublished data.
10. Bloom, B. R., S. B. Snapper, T. Kieser, and W. R. Jacobs, Jr. 1990. Development of recombinant BCG vaccines. Semin. Virol. 1:21-30.
11. Boucher, P., H. Sato, Y. Sato, and C. Locht. 1994. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein. Infect. Immun. 62:449-456.
12. Buchmeier, N. A., and F. Heffron. 1990. Induction of Salmonella stress proteins upon infection of macrophages. Science 248:730-732.
13. Cody, C. L., L. J. Baraff, J. D. Cherry, S. M. Marcy, and C. R. Manclark. 1981. Nature and rates of adverse reactions associated with DTP and DT immunization in infants and children. Pediatrics 68:650-660.
14. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Durdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. JAMA 271:698-702.
15. Connell, N. D., E. Medina-Acosta, W. R. McMaster, B. R. Bloom, and D. G. Russell. 1993. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc. Natl. Acad. Sci. USA 90:11473-11477.
16. Greco, D., S. Salmaso, P. Mastrantonio, M. Giuliano, A. E. Tozzi, A. Anemona, M. L. Ciofi degli Atti, A. Glammanco, P. Panei, W. C. Blackwelder, D. L. Klein, S. G. F. Wassilak, and the Progetto Pertosse Working Group. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341-348.
17. Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:349-355.
18. Honda, M., K. Matsuo, T. Nakasone, V. Okamoto, H. Yoshizaki, K. Kitamura, W. Sugiura, K. Watanabe, Y. Fukushima, S. Haga, Y. Katsura, H. Tasaka, K. Komuro, T. Yamada, T. Asano, A. Yamazaki, and S. Yamazaki. 1995. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl. Acad. Sci. USA 92:10693-10697.
19. Huygen, K., E. Lozes, B. Gilles, A. Drowart, K. Palfliet, F. Jurion, I. Roland, M. Art, M. Dufaux, J. Nyabenda, J. De Bruyn, J.-P. van Vooren, and R. De Leys. 1994. Mapping of TH1 helper T-cell epitopes on major secreted mycobacterial antigen 85A in mice infected with live Mycobacterium bovis BCG. Infect. Immun. 62:363-370.
20. Huygen, K., J. P. van Vooren, M. Turneer, R. Bosmans, P. Diercks, and J. De Bruyn. 1988. Specific lymphoproliferation, gamma interferon production and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand. J. Immunol. 27:187-194.
21. Jenkinson, D. 1988. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br. Med. J. 296:612-614.
22. Kazuhiro, M., R. Yamaguchi, A. Yamazaki, H. Tasaka, K. Terasaka, M. Totsuka, K. Kobayashi, H. Yukitake, and T. Yamada. 1990. Establishment of a foreign antigen secretion system in mycobacteria. Infect. Immun. 58:4049-4054.
23. Kremer, L., A. Baulard, J. Estaquier, J. Content, A. Capron, and C. Locht. 1995a. Analysis of the Mycobacterium tuberculosis 85A antigen promoter region. J. Bacteriol. 177:642-653.
24. Kremer, L., A. Baulard, J. Estaquier, O. Poulain-Godefroy, and C. Locht. 1995b. Green fluorescent protein as a new expression marker in mycobacteria. Mol. Microbiol. 17:913-922.
25. Kremer, L., G. Riveau, A. Baulard, A. Capron, and C. Locht. 1996. Neutralizing antibody responses elicited in mice immunized with recombinant Bacillus Calmette-Guérin producing the Schistosoma mansoni glutathione S-transferase. J. Immunol. 156:4309-4317.
26. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
27. Lambert, H. J. 1965. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep. 80:365.
28. Langermann, S., S. R. Palaszynski, J. E. Burlein, S. Koenig, M. S. Hanson, D. E. Briles, and C. K. Stover. 1994. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J. Exp. Med. 180:2277-2286.
29. Langermann, S., S. R. Palaszynski, A. Sadziene, C. K. Stover, and S. Koenig. 1994. Systemic and mucosal immunity induced by BCG vector expressing an outer-surface protein of Borrelia burgdorferi. Nature 372:552-555.
30. Mills, K. H. G., A. Barnard, J. Watkins, and K. Redhead. 1993. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410.
31. Muray, A., N. Winter, M. Lagranderie, D. F. Hill, J. Rauzier, J. Timm, C. Leclerc, K. M. Moriarty. M. Gheorghiu, and B. Gicquel. 1992. Expression of Escherichia coli β-galactosidase in Mycobacterium bovis BCG using an expression system from Mycobacterium paratuberculosis which induced humoral and cellular immune responses. Mol. Microbiol. 6:3331-3342.
32. + T-cell clones against Bordetella pertussis. Infect. Immun. 59:3768-3773.
33. Plotkin, S. A., and E. A. Mortimer, Jr. (ed.). 1994. Vaccines. WB Saunders, Philadelphia, Pa.
34. Ryan, M., L. Gothefors, J. Storsaeter, and K. H. G. Mills. 1996. B. pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice. Dev. Biol. Stand. 89:251-259.
35. Ryan, M., G. Murphy, L. Gothefors, L. Nilsson, J. Storsaeter, and K. H. G. Mills. 1997. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 Th cells. J. Infect. Dis. 175:1246-1250.
36. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
37. Sato, H., and Y. Sato. 1990. Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect. Immun. 58:3369-3374.
38. Sato, H., A. Ito, J. Chiba, and Y. Sato. 1984. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect. Immun. 46:422-428.
39. Sato, Y., M. Kimura, and H. Fukumi. 1984. Development of a pertussis component in Japan. Lancet i:122-126.
40. Snapper, S. B., R. E. Melton, S. Mustafa, T. Kieser, and W. R. Jacobs, Jr. 1990. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol. Microbiol. 4:1911-1919.
41. Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, S. B. Snapper, R. G. Barletta, W. R. Jacobs, Jr., and B. R. Bloom. 1991. New use of BCG for recombinant vaccines. Nature 351:456-460.
42. Turneer, M., and A. Marchal. 1983. Pouvoirs immunogène et protecteur d'une anatoxine tétanique absorbée. Ann. Méd. Vét. 127:635-642.